Search Results

Andelyn Biosciences has partnered with Grace Science, LLC, to tech transfer and manufacture GS-100, a suspension process AAV NGLY1 gene therapy for Phase I/II/III clinical trial material for the treatment of NGLY1 Deficiency.

Grace Science, LLC announced today that the IND for GS-100, an AAV9 gene therapy for NGLY1 Deficiency, was accepted into the FDA’s Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program.

NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024.

Prime Therapeutics LLC and Magellan Rx Management launched Pharmacy Match, a technology-enabled specialty pharmacy solution designed to drive competition through an expanded specialty pharmacy network and to lower drug costs for plan sponsors.

SHINE Technologies, LLC, a pioneer in next-generation fusion-based technology, becomes North America’s largest producer of non-carrier added lutetium-177 chloride, a cutting-edge radiopharmaceutical used in precision cancer treatment, with a Drug Master File to the U.S. Food and Drug Administration.

Integrated Oncology Network, LLC (“ION”), a portfolio company of Silver Oak Services Partners, LLC (“Silver Oak”), today announced the acquisition of Urology Partners, LLC.

Wexford Science & Technology, LLC announced that the National Institutes of Health has signed a lease at 850 PBC and will use the space to accommodate the Phoenix Epidemiology & Clinical Research Branch of the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases.